RE:RE:RE:RE:RE:RE:RE:RE:At 2.48pm today - a big head fake.Makes sense. It should make it to $50 easily on anything substantially positive as there is such a dark cloud over this stock due to what happened. If they finally can get a deal, that means a major has done their rigorous due diligence and are confident that they will pass the BLA requirements. So, it could even start a fire back to higher levels. But, and there are a lot of buts, there is only a few months before they need money and SALP has offered a line of credit and we know what happened last time. So, I am hopeful that the great potential comes out in Ryplazim and 4050 but I have my doubts as someone should have been interested in mid 2018 with the many good results they had even if there was no placebo tests. Obviously, those non-placebo tests were used against them in negotiations with Boehringer but I would have signed a low $$ upfront and big milestone payments. Not sure why they couldnt get it done when so much was riding on it.
ualcin1 wrote: stockbuphoon: I keep them. Last year, I took advantage of the warrants that were offered to us, to the point that I was able to neutralize (almost) the dilution that the financial rearrangement of TV had caused. I therefore find myself with an average acquisition cost of $50, which represents, in pre-arrangement dollars, about $1. Prometic has long hovered around this $1 value, after, I must point out, Pierre Laurin's exaggerations were brought to light. That Liminal's stock goes back up to this $1 value (thus to $50 in current dollars) does not seem out of reach to me. Let's remember that in Pierre Laurin's triumphant era (the famous "over-pregnancy"), this stock had reached more than $3, or $150 in post-arrangement dollars. Am I too optimistic? Maybe. But my intuition leads me to remain confident. In any case, I don't have much choice: if I sold now, my losses would be much too high. So I try to be patient...
<br /> <br />